Stereotaxis, Inc. (Stereotaxis) has appointed Daniel J. Johnston as its new chief financial officer (CFO), effective November 15, 2009. He will join Stereotaxis in September, 2009. Daniel Johnston succeeds James M. Stolze, who will retire from the company as CFO, effective year-end 2009. Johnston brings over 15 years of senior financial management experience, including the position of CFO at three manufacturing companies.
Dan has a wealth of corporate management and financial experience with growing industrial and consumer products companies, said Michael P. Kaminski, president and chief executive officer of Stereotaxis. He is a hands-on operational manager with strong financial and organizational skills. His experience ranges from creating organizations and processes in a start-up phase, to financial structuring in both the public and private markets and management of a broad range of domestic and international organizations. We are very excited that Dan has agreed to join Stereotaxis and believe he will be instrumental in taking Stereotaxis to the next level.
I would also like to thank Jim Stolze for his many contributions to Stereotaxis. During the more than five years that Jim has served as CFO of our Company, he has been a key player in our success in driving revenue, reducing expenses and enhancing efficiencies in the organization. We are very pleased that Jim has agreed to serve as a consultant for Stereotaxis through June 2011, Kaminski concluded.
Johnston currently serves as the executive vice president and CFO of united Components, Inc., a position he has held since 2007. Prior to this, he was vice president and CFO of Solae Company. Before joining Solae Company in 2006, Johnston spent 11 years, including eight as CFO, at United Industries, a manufacturer of diversified consumer packaged goods. Johnston has a B.S. degree from the University of Missouri and is a certified public accountant.
Stereotaxis designs, manufactures and markets an advanced cardiology instrument control system for use in a hospital’s interventional surgical suite to enhance the treatment of coronary artery disease and arrhythmias.